The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.

A second tocilizumab biosimilar has been launched in the US, with Bio-Thera and Biogen together introducing their Tofidence version just weeks after Fresenius Kabi launched its first-to-market Tyenne.

The European Medicines Agency believes Idorsia’s Jeraygo should be approved for use in the EU at two different doses rather than just the one approved by the US Food and Drug Administration last month.

Bio-Thera Solutions has struck a deal with Macter International for rights to its BAT1706 biosimilar rival to Avastin (bevacizumab) in Pakistan and Afghanistan.